Shares of Versartis Inc. (NASDAQ:VSAR) traded up 3% on Wednesday . The stock traded as high as $11.64 and last traded at $11.45, with a volume of 50,798 shares changing hands. The stock had previously closed at $11.12.

Several analysts have weighed in on the company. Morgan Stanley reissued a “hold” rating on shares of Versartis in a report on Saturday, April 30th. Zacks Investment Research lowered Versartis from a “hold” rating to a “sell” rating in a report on Wednesday, May 4th. Canaccord Genuity reissued a “buy” rating on shares of Versartis in a report on Tuesday, May 10th. Finally, Northland Securities assumed coverage on Versartis in a report on Thursday, April 7th. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. Versartis currently has a consensus rating of “Hold” and an average price target of $17.20.

The company’s market cap is $344.31 million. The stock’s 50 day moving average is $10.85 and its 200 day moving average is $9.33.

Versartis (NASDAQ:VSAR) last announced its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.03. Analysts anticipate that Versartis Inc. will post ($3.29) EPS for the current fiscal year.

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.